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Abstract
Objective—To evaluate the comparability and responsiveness of PROMIS Fatigue Item Bank 
across six chronic conditions.
Study Design and Setting—Individuals (n=1,430) with chronic obstructive pulmonary disease 
(COPD; n=125), chronic heart failure (CHF; n=60), chronic back pain (n=218), major depressive 
disorder (MDD; n=196), rheumatoid arthritis (RA; n=521), and cancer(n=310) completed 
assessments from the PROMIS fatigue item bank at baseline and a clinically-relevant follow-up. 
The cancer and arthritis samples were followed in observational studies; the other four groups 
were enrolled immediately prior to a planned clinical intervention. All participants completed 
global ratings of change at follow-up. Linear mixed effects models and standardized response 
means were estimated to examine clinical validity and responsiveness to change.
Results—All patient groups reported more fatigue than the general population (range = 0.2 – 
1.29 SD worse). The four clinical groups with pre-treatment baseline data experienced significant 
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improvement in fatigue at follow-up (effect size range= 0.25 to 0.91). Individuals reporting better 
overall health usually experienced larger fatigue changes than those reporting worse overall health.
Conclusion—The results support the PROMIS fatigue measures’s responsiveness to change in 
six different chronic conditions. In addition, these results support the ability of the PROMIS 
fatigue measures to compare differences in fatigue across a range of chronic conditions, thereby 
enabling comparative effectiveness research.
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1. Introduction
Fatigue is a symptom commonly experienced by healthy individuals as well as those with 
chronic disorders. When experienced as part of a chronic condition, it is often experienced 
as overwhelming, debilitating, and exhausting; decreasing one’s ability to carry out daily 
activities, including the ability to work effectively and to function at one’s usual level in 
family or social roles.[1–4] A growing body of literature documents the high prevalence of 
fatigue and its impact across a variety of chronic health conditions, including back pain,[5] 
cancer,[6, 7] congestive heart failure (CHF),[8] chronic obstructive pulmonary disease 
(COPD),[9] major depressive disorder (MDD),[10, 11] and rheumatoid arthritis (RA).[12] 
Its prevalence makes it a common treatment target, as relieving fatigue often results in 
improved well-being and function across a large number of people.
The World Health Organization (WHO)’s International Classification of Functioning, 
Disability and Health included the minimization of fatigue among its stated aims,[13] 
highlighting the importance of regular assessment of fatigue in both research and clinical 
contexts. Although a number of disease-specific fatigue measures exist,[14–17] a well-
developed and carefully-calibrated universal fatigue measure that can be applied across 
chronic health populations and treatment contexts could enhance the comparability of 
findings and thus serve as a common metric of fatigue across chronic health condition 
groups. This would greatly enhance the interpretability of fatigue results across clinical 
research studies, and enable meaningful comparative effectiveness research.
To this end, the Patient-Reported Outcomes Measurement Information System® (PROMIS®) 
investigators utilized a multi-step, mixed methods approach to develop a fatigue item bank 
which can be used as an assessment tool as either a computerized adaptive test (CAT) or a 
fixed-length short form. The development process and psychometric properties of the fatigue 
item bank have been reported previously.[18–20] In this paper, we describe the longitudinal 
clinical validation of the fatigue item bank in adults in six different chronic health condition 
samples: back pain, cancer, CHF, COPD, MDD, and RA. We hypothesized that these 
clinical samples would present with more fatigue than is found in the general US population. 
We also hypothesized that clinical samples with baseline (pre-treatment) data available, who 
were embarking on a new or modified treatment plan (i.e., treatment for back pain; CHF; 
COPD patients in an acute exacerbation of symptoms; MDD), would experience 
longitudinal improvements in fatigue. We also predicted relative stability in fatigue scores 
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over time among other clinical samples being followed naturalistically (i.e., COPD-stable 
patients; cancer; RA), or in clinical stituations where some patients would be expected to 
improve, some would be expected to worsen, and many would not be expected to change 
(e.g., RA, stable COPD). Finally, we hypothesized that fatigue scores would differentiate 
subsets of samples that were distinct in terms of clinical severity or functional impairment 
(e.g., COPD-stable versus COPD-exacerbation).
2. Methods
2.1. Clinical samples
Included in this report are data collected across six studies (back pain, cancer, CHF, COPD, 
MDD, and RA), conducted by PROMIS investigators. The studies of MDD, back pain, and 
CHF followed patients as they enrolled in new treatments. Patients with acute COPD 
exacerbation were expected to experience symptom resolution over the course of the study. 
Both RA and cancer samples were heterogeneous with respect to intervention, but were 
dominated by participants who were already receiving treatments by the time they enrolled 
in the current study. We examined the longitudinal data at baseline and follow-up, namely, 3 
months after start of study (MDD, back pain, and COPD), 8–12 weeks after heart 
transplantation (CHF), 6–12 weeks after enrollment (cancer), and 12 months after 
enrollment (RA). Although the COPD-stable, cancer, and RA groups were not enrolled in 
new treatments, we apply the clinical trial terms “baseline” and “follow-up” to all study 
groups for consistency. Details of the sample information and recruitment procedures are 
described in Cook et al.[21] (this volume).
2.2. PROMIS Fatigue item bank
The PROMIS Fatigue item bank is comprised of 95 items, including the 13-item FACIT-
Fatigue,[14] calibrated from an initial pool of 112 items tapping two conceptually related 
areas: fatigue experience and fatigue interference in daily life and function.[18] Higher 
scores suggest worse fatigue. CAT and short-forms derived from the item bank can reliably 
estimate fatigue, with scores referenced to the US general population using the T-score 
metric, with mean=50 and standard deviation (SD)=10. Fatigue T-scores were estimated via 
CAT for patients enrolled in the CHF, COPD, back pain, and MDD studies. In cancer and 
RA, Fatigue T-scores were obtained using the PROMIS Fatigue short-form version 1. Since 
both short-form and CAT used the same item parameters as used by the PROMIS Fatigue 
item bank, their resulting fatigue scores are comparable.[18] PROMIS Fatigue items are 
available in an online Appendix.
2.2. Statistical analyses
Analyses to evaluate responsiveness to change were conducted separately for each of seven 
clinical groups: back pain, cancer, CHF, COPD-exacerbation, COPD-stable, MDD, and RA. 
Items measuring general health (e.g., In general, would you say your health is: Excellent, 
Very Good, Good, Fair, or Poor) were used to estimate patient-perceived responsiveness for 
each condition. For these items, the baseline and follow-up scores were subtracted to find 
change scores. In addition, fatigue specific global change items were used to evaluate 
responsiveness for cancer and RA (e.g., “Since the last time you filled out a questionnaire, 
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your level of fatigue is: very much better, moderately better, a little better, about the same, a 
little worse, moderately worse, or very much worse”). For change scores of general health 
items and fatigue global change items, scores were grouped into three categories - better, 
about the same, and worse – for the responsiveness analyses.
Linear mixed models were estimated with random subject effects to account for the 
similarity among repeated observations within individuals.[22, 23] Missing data were 
evaluated prior to performing longitudinal analyses. Since it was reasonable to consider the 
missing data to be missing completely at random (MCAR) or missing at random (MAR), a 
mixed model is advantageous because all available data can be used; in other words, the 
analyses were not restricted to only those respondents with data at both time points.[24, 25] 
Least squares means, standard errors and 95% confidence intervals were estimated from the 
models.
Change scores in the PROMIS Fatigue T-scores (both from CAT and SF) were used to 
estimate the standardized response mean (SRM) for each of the three change groups. This is 
the ratio of the mean change to the standard deviation of that change.[26] It is a form of 
Cohen’s effect size index.[27] We set an SRM of 0.30 as the minimum required magnitude 




A total of 1,430 people participated in the clinical studies. Participants were diverse in terms 
of gender, age and marital status, as reported in the overview paper in this issue (this 
volume).[21] Most participants were non-Hispanic White, had some college education, and 
had moderate to severe health limitations. At baseline, participants from all studies reported 
more fatigue, ranging from 2–13 T-score points (i.e.,0.2 – 1.3 SD on the T-score metric) 
higher than the US population norm (score of 50). Significantly different fatigue scores were 
reported across these conditions, F=34.97, p<.0001. Specifically, COPD-exacerbation group 
reported significantly (p<0.05) more fatigue than back pain, COPD-stable, RA and Cancer. 
MDD group reported significantly (p<0.05) more fatigue than back pain, COPD-stable, RA, 
and Cancer. CHF group reported significantly (p<0.05) more fatigue than RA and Cancer. 
Fatigue T-scores of each condition were 56.7 (SD=9.4) for back pain, 52.0 (SD=7.6) for 
cancer, 58.9 (SD=10.4) for CHF, 62.8 (SD=8.3) for COPD-exacerbation, 56.3 (SD=8.6) for 
COPD-stable, 61.3 (SD=8.3) for MDD, and 53.8 (SD=8.8) for RA (see Table 1a).
3.2. Responsiveness
Data from those who completed the follow-up assessments (87.6%; n=1,252) were used for 
responsiveness analyses. All four diagnostic groups that were enrolled in single-arm 
intervention studies (COPD; CHF; MDD; back pain) experienced predicted significant 
improvement in fatigue over time. The two groups enrolled in observational studies (cancer; 
RA) did not have group-wide changes in their fatigue levels over time. Group-wide fatigue 
change were not predicted in these two cohorts. Rather, we divided these two groups into 
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improved and worsened subgroups based on patient-reported global ratings of change in 
fatigue at follow-up. The results of the mixed models are summarized in Tables1a and 1b. 
Least squares means from baseline to time 2 are shown in Figure 1. Estimated mean change 
scores for the improving groups ranged from 2.4 (COPD-Stable) to 11.6 (CHF). Negligible 
change scores were found on RA (0.40) and slightly more fatigue was found on Cancer 
(1.16 points) when they were evaluated as a whole. Yet, when evaluating both groups by 
subgroups, change scores for improved groups were −0.27 and −1.17, while change scores 
for worsened groups were 1.44 and 4.67 for RA and Cancer, respectively.
For most participants who reported that their overall health and fatigue (for Cancer, CHF, 
COPD-exacerbation, COPD-stable and RA) changed for the better, there was a 
corresponding improvement in fatigue over time with T-score changes ranging from −0.35 
(RA) to −11.9 (CHF) (standardized response means ranged from −0.06 to −1.23; see Table 
2). Effect sizes (i.e., SRM) for those who reported better overall health (i.e., global health) or 
fatigue at follow up were always larger than effect sizes for those who reported worse 
overall health except for Cancer (both overall health and fatigue) and RA (fatigue only). Yet, 
mixed responses were found for those who reported their overall health and fatigue 
worsened or were about the same. Only the change scores of the RA patients and cancer 
patients showed significantly worse fatigue scores at follow-up (Table 2).
4. Discussion
The PROMIS Fatigue item bank was developed using rigorous methods, demonstrates good 
psychometric properties, and is publicly available.[18] The present study extends the intial 
published information on reliability and validity by examining the longitudinal validation of 
the PROMIS Fatigue item bank in six chronic conditions, thus providing support for the 
clinical validity of PROMIS fatigue measures. The findings also highlight the ability to 
meaningfully compare fatigue levels across chronic disease samples, providing an evidence 
base to support the setting of responder definitions and to enable comparative effectiveness 
research that relies upon cross-disease comparisons, or within-disease comparisons across 
treatments.
Responsiveness, or sensitivity to detect change in fatigue over time and in response to 
clinical intervention, represents an important attribute for fatigue PROs and remains 
essential for their acceptance in clinical research and practice. Moreover, the ability to detect 
bidirectional fatigue change in terms of improvement and deterioration, while 
acknowledging score variability unrelated to change (i.e., error), constitute important 
characteristics of fatigue measures. In the present study, PROMIS fatigue scores improved 
over time in all four groups that were enrolled into single-arm trials that were designed to 
detect clinically-anticipated improvement at the group level. This included CHF, back pain, 
MDD, and COPD-exacerbation samples. This is consistent with our hypothesis that clinical 
samples undergoing condition-targeted interventions would report a post-treatment decrease 
in fatigue relative to baseline. The improvement in PROMIS fatigue noted in the COPD-
stable subgroup was not expected. It is possible that this subgroup improved slightly due to 
change in management initiated at the baseline visit, or that the improved score (although 
lower in magnitude than that observed in the other clinical groups, including the COPD 
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exacerbation group) was a random (chance) observation. The low magnitude of 
improvement (2.4 units) relative to the others (range = 3.5 – 11.6 units) is of a magnitude 
that may not be clinically meaningful. For example, Yost et al estimated the minimally 
important difference of two PROMIS fatigue instruments to be in the range of 2.5–5.0 
points.[30] By contrast, the very large fatigue improvement in CHF patients (Table 2; SRM 
>1.0) might reflect a uniquely dramatic benefit of a major surgical intervention for this 
condition. Further research can evaluate the magnitude of benefit of other surgical and 
medical treatment options for CHF and associated fatigue.
The responsiveness analyses for arthritis and cancer samples centered around the patients’ 
global rating of change. In both cases, and in both directions of change (improvement and 
worsening), we observed changes in the PROMIS fatigue scores in the predicted direction. 
These changes were statistically significant for those patients who said they were worse on 
the fatigue-specific global question, but not for those patients who said they were better. 
This asymmetry (i.e., relative to worsening change scores, smaller improvement change 
scores are considered meaningful to patients) has been noted previously.[31] Interestingly, 
PROMIS fatigue change scores associated with patients who said they felt generally better 
or generally worse were also consistently in the predicted direction, and in the case of 
people who reported feeling globally better, were of a higher magnitude than the fatigue-
specific global rating (Table 2).
These findings provide evidence to suggest that the PROMIS fatigue measures used in these 
studies are clinically valid and allow for direct comparisons across six common chronic 
conditions. Regarding responsiveness to change, the PROMIS fatigue measures used across 
these studies detected upward and downward change in most cases. Moreover, the findings 
suggest that the PROMIS fatigue measures are robust to non-change related variability 
among clinical samples whose conditions would not be expected to change substantially 
over time, except COPD-stable as discussed above.
The ability for PROMIS fatigue measures to differentiate between subgroups of a clinical 
sample that differ in severity constitutes another important characteristic when evaluating 
clinical validity. The present study provided the opportunity to examine this question by 
comparing fatigue scores between the COPD-stable and COPD-exacerbation group. As 
hypothesized, the COPD-exacerbation subgroup reported significantly greater fatigue than 
their COPD-stable counterparts at both baseline and follow-up. We also predicted that these 
two groups would differ in longitudinal fatigue changes, with expected improvement in 
fatigue scores for the COPD-exacerbation group, but not the COPD-stable group. Although 
the findings demonstrated unexpected improvement in fatigue over time in this COPD-stable 
group, it should be noted that the magnitude of fatigue improvement in the COPD-stable 
group was smaller than the magnitude of improvement among the COPD-exacerbation, thus 
reflecting relatively greater stability of fatigue over time in the COPD-stable group when 
compared to the COPD-exacerbation. This pattern of findings indicates that the PROMIS 
fatigue measure is sensitive to detect differences between subgroups of a clinical sample 
with varying severity levels.
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When considering the results of this study, several limitations should be noted. First, none of 
the four planned intervention studies included a control group. As a result, we cannot 
differentiate the intervention effect from a placebo effect; such a determination can only be 
made with a randomized controlled trial. Small sample sizes (n<5) in some cells might not 
provide enough statistical power which may have affected the interpretation of results. 
Because of their inherently uncontrolled nature, observational studies are not ideal for 
evaluating responsiveness of outcome measures such as those evaluated here. Second, the 
use of patient global ratings of change, while face valid and clinically-relevant, comes with 
some problems of methodology and interpretation. Because they are gathered at follow-up, 
global ratings of change are typically more highly-correlated with post-test than they are 
with pretest, or with the change score itself.[32] Nevertheless, they provide a useful starting 
“anchor” for estimating the magnitude of measured change that is important to patients at 
follow-up assessment.
Despite these limitations, the present study extends previous validation of the PROMIS 
fatigue measure by examining longitudinal change in scores across a diverse set of clinical 
samples. This provided the opportunity to assess the clinical validity of this measure by 
examining responsiveness to change following a treatment intervention, examining stability 
of fatigue scores over time in stable clinical conditions not receiving an intervention, and by 
examining differences in fatigue scores between different severity level subgroups of the 
same chronic condition. Although full clinical validity remains a dynamic construct which is 
never fully achieved, but rather continuously examined, the present study provides an 
important step in facilitating the productive application of the PROMIS fatigue measures in 
clinical care and research, most particularly comparative effectiveness research.
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• PROMIS Fatigue item bank is a valid tool to measure fatigue experienced by 
people with diverse chronic conditions.
What this adds to what was known?
• PROMIS Fatigue measures can detect change over time in people with a range 
of chronic conditions.
What is the implication and what should change now?
• These results provide an important step in facilitating the use and acceptance of 
the PROMIS fatigue measures in clinical practice and comparative effectiveness 
research.
• PROMIS Fatigue measures are publicly available (www.assessmentcenter.net). 
Custom short forms can be designed and scored using PROMIS item response 
theory calibrations.
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Change in PROMIS Fatigue T-scores Across Clinical Samples
CHF=Chronic heart failure; COPD=Chronic Obstructive Pulmonary Disease; Scores 
reported are on the T-score metric as referenced to the US general population (mean=50; 
SD=10).[34] Higher scores reflect more fatigue.
NOTE:
1. Cancer (group 1 n=81) : patients reported more (worse) fatigue at follow-up rated by the 
fatigue-specific global change item. Cancer (group 2 n=84) : patients reported less (better) 
fatigue at follow-up rated by the fatigue-specific global change item.
2. RA (group 1 n=171) :rhemautoid patients who reported more (worse) fatigue at follow-up 
rated by the fatigue-specific global change item. RA (group 2 n=48) :rhemautoid patients 
reported less (better) fatigue at follow-up rated by the fatigue-specific global change item.
Cella et al. Page 11
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